GuidelineLa Radiologia medica2025
Italian adaptation of the European guidelines for breast cancer diagnosis, staging, and preoperative planning: a GRADE-ADOLOPMENT approach.
Guideline in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An Italian guideline panel issued the national recommendations for breast cancer diagnosis, staging, and preoperative planning. The panel employed the ADOLOPMENT process to adopt or adapt the guidelines developed by the European Commission Initiative on Breast Cancer (ECIBC). This process utilises the Grading of Recommendations Assessment, Development and Evaluation evidence-to-decision framework. Hereby, we present 15 prioritised recommendations from the second chapter of the Italian guidelines. All of the recommendations as originally developed by the ECIBC were adopted. For the assessment of women with positive screening result, the diagnostic recommendations suggest using digital breast tomosynthesis instead of additional mammographic projections. Recommendations include using needle core biopsy (NCB) instead of fine-needle aspiration for suspicious lesions, and stereotactic-guided -rather than ultrasound-guided- NCB for suspicious calcifications. For preoperative planning, they recommend clip marking after biopsy and not using additional magnetic resonance imaging (MRI) for confirmed ductal carcinoma in situ. Contrast-enhanced mammography is preferred over MRI for presurgical planning, when needed. Other imaging tests are not recommended for stage I, IIa, and IIb BC without signs of metastasis, while positron emission tomography-computed tomography alone is suggested for stage III BC. Adjuvant hormone therapy is recommended when 1% or more tumour cells show oestrogen or progesterone receptor positivity, which replaces the 10% threshold. Adopting shared and trustworthy guidelines for BC screening across Europe will help standardise the process across settings and advance healthcare quality and equity.
Indexed as
Identifiers
40824613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.